These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

392 related articles for article (PubMed ID: 15235598)

  • 21. Recovery from polyglutamine-induced neurodegeneration in conditional SCA1 transgenic mice.
    Zu T; Duvick LA; Kaytor MD; Berlinger MS; Zoghbi HY; Clark HB; Orr HT
    J Neurosci; 2004 Oct; 24(40):8853-61. PubMed ID: 15470152
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Boat, an AXH domain protein, suppresses the cytotoxicity of mutant ataxin-1.
    Mizutani A; Wang L; Rajan H; Vig PJ; Alaynick WA; Thaler JP; Tsai CC
    EMBO J; 2005 Sep; 24(18):3339-51. PubMed ID: 16121196
    [TBL] [Abstract][Full Text] [Related]  

  • 23. ORMOSIL nanoparticles as a non-viral gene delivery vector for modeling polyglutamine induced brain pathology.
    Klejbor I; Stachowiak EK; Bharali DJ; Roy I; Spodnik I; Morys J; Bergey EJ; Prasad PN; Stachowiak MK
    J Neurosci Methods; 2007 Sep; 165(2):230-43. PubMed ID: 17655935
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neurodegeneration: a case of arrested development?
    La Spada AR
    Cell; 2006 Nov; 127(4):669-71. PubMed ID: 17110325
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Spinocerebellar ataxia type 1.
    Donato SD; Mariotti C; Taroni F
    Handb Clin Neurol; 2012; 103():399-421. PubMed ID: 21827903
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Focused cerebellar laser light induced hyperthermia improves symptoms and pathology of polyglutamine disease SCA1 in a mouse model.
    Hearst SM; Shao Q; Lopez M; Raucher D; Vig PJ
    Cerebellum; 2014 Oct; 13(5):596-606. PubMed ID: 24930030
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neurodegeneration in the polyglutamine diseases: Act 1, Scene 1.
    Nussbaum R; Auburger G
    Nat Neurosci; 2000 Feb; 3(2):103-4. PubMed ID: 10649562
    [No Abstract]   [Full Text] [Related]  

  • 28. RNA interference as potential therapy for neurodegenerative disease: applications to inclusion-body myositis?
    Paulson H
    Neurology; 2006 Jan; 66(2 Suppl 1):S114-7. PubMed ID: 16432138
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Interferon β induces clearance of mutant ataxin 7 and improves locomotion in SCA7 knock-in mice.
    Chort A; Alves S; Marinello M; Dufresnois B; Dornbierer JG; Tesson C; Latouche M; Baker DP; Barkats M; El Hachimi KH; Ruberg M; Janer A; Stevanin G; Brice A; Sittler A
    Brain; 2013 Jun; 136(Pt 6):1732-45. PubMed ID: 23518714
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The histone deacetylase HDAC3 is essential for Purkinje cell function, potentially complicating the use of HDAC inhibitors in SCA1.
    Venkatraman A; Hu YS; Didonna A; Cvetanovic M; Krbanjevic A; Bilesimo P; Opal P
    Hum Mol Genet; 2014 Jul; 23(14):3733-45. PubMed ID: 24594842
    [TBL] [Abstract][Full Text] [Related]  

  • 31. ATAXIN-1 interacts with the repressor Capicua in its native complex to cause SCA1 neuropathology.
    Lam YC; Bowman AB; Jafar-Nejad P; Lim J; Richman R; Fryer JD; Hyun ED; Duvick LA; Orr HT; Botas J; Zoghbi HY
    Cell; 2006 Dec; 127(7):1335-47. PubMed ID: 17190598
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The AXH domain of Ataxin-1 mediates neurodegeneration through its interaction with Gfi-1/Senseless proteins.
    Tsuda H; Jafar-Nejad H; Patel AJ; Sun Y; Chen HK; Rose MF; Venken KJ; Botas J; Orr HT; Bellen HJ; Zoghbi HY
    Cell; 2005 Aug; 122(4):633-44. PubMed ID: 16122429
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hosting neurotoxicity in polyglutamine disease.
    Liu N; Bonini NM
    Cell; 2006 Dec; 127(7):1299-300. PubMed ID: 17190592
    [TBL] [Abstract][Full Text] [Related]  

  • 34. SCA1 transgenic mice: a model for neurodegeneration caused by an expanded CAG trinucleotide repeat.
    Burright EN; Clark HB; Servadio A; Matilla T; Feddersen RM; Yunis WS; Duvick LA; Zoghbi HY; Orr HT
    Cell; 1995 Sep; 82(6):937-48. PubMed ID: 7553854
    [TBL] [Abstract][Full Text] [Related]  

  • 35. miR-19, miR-101 and miR-130 co-regulate ATXN1 levels to potentially modulate SCA1 pathogenesis.
    Lee Y; Samaco RC; Gatchel JR; Thaller C; Orr HT; Zoghbi HY
    Nat Neurosci; 2008 Oct; 11(10):1137-9. PubMed ID: 18758459
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Biomedicine. Ataxin-1 regulators in the spotlight.
    Heintz N
    Science; 2003 Jul; 301(5629):59-60. PubMed ID: 12843383
    [No Abstract]   [Full Text] [Related]  

  • 37. Intranuclear immunolocalization of 14-3-3 protein isoforms in brains with spinocerebellar ataxia type 1.
    Umahara T; Uchihara T; Yagishita S; Nakamura A; Tsuchiya K; Iwamoto T
    Neurosci Lett; 2007 Mar; 414(2):130-5. PubMed ID: 17224237
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impairment of spinal motor neurons in spinocerebellar ataxia type 1-knock-in mice.
    Takechi Y; Mieda T; Iizuka A; Toya S; Suto N; Takagishi K; Nakazato Y; Nakamura K; Hirai H
    Neurosci Lett; 2013 Feb; 535():67-72. PubMed ID: 23328439
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Expression of ataxin-7 in CNS and non-CNS tissue of normal and SCA7 individuals.
    Jonasson J; Ström AL; Hart P; Brännström T; Forsgren L; Holmberg M
    Acta Neuropathol; 2002 Jul; 104(1):29-37. PubMed ID: 12070661
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Decreased expression of glutamate transporter GLAST in Bergmann glia is associated with the loss of Purkinje neurons in the spinocerebellar ataxia type 1.
    Cvetanovic M
    Cerebellum; 2015 Feb; 14(1):8-11. PubMed ID: 25255716
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.